file:///C|/Documents%20and%20Settings/user29/Desktop/Conference%20on%204th%20Lyophilisation%202010.txt
4th Lyophilisation Workshop Ensuring optimum formulations for pharmaceuticals and biologicals 7th - 9th September 2010, BSG Conference Centre, London, UK Key Speakers Filippo Orlandi, Sterile Manufacturing Manager, GlaxoSmithKline Otmane Bousif, Head, Formulation Development – Biotech Products, Sanofi -Aventis Richard Storey, Associate Principal Scientist, AstraZeneca Patrick Garidel, Head of Pharmaceutical Basic Development, Boehringer Ingelheim Pharma GmbH & Co. KG Joanne Broadhead, Team Manager, Liquids Manufacturing, AstraZeneca Miguel Galan, Innovation & R&D Director, Telstar Lyo Maik Guttzeit, Team Leader, Validation, GEA Lyophil Paul Matejtschuk, Principal Scientist, Standardisation Science, National Institute for Biological Standards and Control Kevin Ward, Director of Research and Development, BioPharma Technology Andrew Parker, Associate Director, Molecular Profiles Introduction 4th Lyophilisation Workshop With over 130 products on the market worth $50bn, biologicals and biopharmaceuticals remain the fastest growing segment amongst novel pharmaceutical entities today1, 2. Mirroring this trend, the market for lyophilising these compounds, currently approaching 200 million units3, is set to continue its year-on-year double digit growth. Without lyophilisation, 60% of biotherapeutics including recombinant proteins, plasma, vaccines and antibodies could not be commercially available3. Freeze-drying has become increasingly efficient in recent years, easier to use, more cost-effective and extremely accurate. It imparts higher stability, broader temperature tolerance, and longer shelf life to pharmaceutical formulations unstable in aqueous solution4.
file:///C|/Documents%20and%20Settings/user29/Desktop/Conference%20on%204th%20Lyophilisation%202010.txt (1 of 3)7/26/2010 3:00:40 PM
file:///C|/Documents%20and%20Settings/user29/Desktop/Conference%20on%204th%20Lyophilisation%202010.txt
Although the commonest way to ensure longevity and stability for complex molecules, lyophilisation however remains costly, complex and facility-intensive. Fine-tuning cycle parameters and trial-and-error experimentation also means the procedure remains as much of an art as a science5. As reducing development time becomes increasingly important in today’s economic climate, a rational, empirical approach to cycle design can save you time and money, especially when upscaling. More importantly, a robust lyophilization cycle will guarantee a safe and effective product. Mastering these complex and inter-related requirements is no mean feat and Visiongain’s 4th Lyophilisation conference provides distilled intelligence on formulation and process development for biopharmaceuticals. With a workshop and sessions led by experts, you will gain a thorough understanding to provide the best outcome for your organisation. Case studies from industry will offer strategic insights to help you optimise key input and output parameters, and troubleshoot challenges with temperature-sensitive moieties or solid proteins. Whether your interests lie in drug formulation, process engineering or strategic partnering, attending this conference will enable you to: • Develop rational approaches to pre-formulation processes for small molecule drugs and biologicals • Exploit advanced scale-down and factorial DoE for formulation optimisation • Design accurate product-specific freezing, sublimation and desiccation protocols • Overcome low-temperature and drying-induced protein denaturation and aggregation • Streamline analytical methodology to accurately predict and accelerate product stability • Meet cGMP, QbD, QC and QA requirements and deliver consistent product quality • Improve process engineering dynamics and scale up • Troubleshoot manufacturing problems • Implement PAT confidently and effectively in manufacturing and the laboratory • Resolve challenges facing today’s industry • Engage industry experts and cement new alliances Who will be there? Presidents, Chief Executive Officers, Vice Presidents, Chief Scientific Officers, Directors, Business Development Managers, and Principal Scientists of: • Vaccine/antibody/cell manufacturing • Bioprocess research and development • Chemical Engineering • Process implementation and process engineering • Stability testing • Sterile production • Quality assurance and quality control • Standardisation science • Drug formulation • Active pharmaceutical ingredients • Pharmaceutical production file:///C|/Documents%20and%20Settings/user29/Desktop/Conference%20on%204th%20Lyophilisation%202010.txt (2 of 3)7/26/2010 3:00:40 PM
file:///C|/Documents%20and%20Settings/user29/Desktop/Conference%20on%204th%20Lyophilisation%202010.txt
• Manufacturing and engineering • Licensing • Product development • Outsourcing/contract manufacturing • Dried technology • Packaging and labelling • Pilot plant operations Workshop Pre-conference Workshop, Tuesday 7th September 2010 PAT for lyophilisation The purpose of the workshop is to allow you to engage in knowledge sharing with your peers in a smaller, less formal environment than the main conference. As such, the audience size will typically be no more than 20 participants in order to enable maximum interaction between the workshop leader and the delegates. The format is also more interactive, with less emphasis on ‘lecture-style’ presentations and more emphasis on group discussions, exercises and Q&A sessions. For more information visit http://www.bharatbook.com/detail.asp?id=135237&rt=Conference-on-4th-Lyophilisation-2010Workshop.html OR Contact us at 207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India. Phone : +91 22 2757 8668 / 2757 9438 Fax : +91 22 2757 9131 E-mail : info@bharatbook.com Website : www.bharatbook.com Follow us on twitter: http://twitter.com/3bbharatbook Please visit our blog at http://bharatbookseo.blogsome.com
file:///C|/Documents%20and%20Settings/user29/Desktop/Conference%20on%204th%20Lyophilisation%202010.txt (3 of 3)7/26/2010 3:00:40 PM